Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

A pair of artificial intelligence algorithms from Boston Scientific and Medtronic ... a toolkit dedicated to providing at-home monitoring for people living with heart failure.

We recently compiled a list of the 8 Hot Growth Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific expands heart implant TV campaign ... from the moment we activated to when I got home and since. No longer do I have to worry about ... do I have enough pads on, do I have ...

Massachusetts-based Boston Scientific generates most of its revenue from sales of its heart devices, such as pacemakers and stents. It also makes equipment to diagnose and treat a range of ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...

Yet, with launches from J&J and Medtronic on the horizon, Needham analysts said Boston Scientific’s electrophysiology growth will slow significantly in 2025. With PFA competition set to increase, ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.